ArticleJournal of translational medicine2026
EDL6D, a bioactive peptide phenocopying SHBG-associated metabolic effects: a new preclinical lead compound for treating the metabolic dysfunction-associated fatty liver disease.
Article in Journal of translational medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundLow plasma sex hormone-binding globulin (SHBG) levels are commonly observed in metabolic dysfunction-associated fatty liver disease (MASLD), a spectrum of disorders ranging from simple hepatocellular steatosis to steatohepatitis, fibrosis, and irreversible cirrhosis. We have previously demonstrated that SHBG overexpression reduces hepatic lipid accumulation by inhibiting lipogenesis both in vitro and in vivo.
methodsIn the present proof-of-concept study, we have developed a bioactive peptide that phenocopies SHBG-associated metabolic effects (EDL6D) and have evaluated its ability to inhibit lipogenesis in vitro using HepG2 cells treated daily with 30 mM fructose. In addition, we assessed the preventive and therapeutic effects of EDL6D in vivo in wild-type mice with MASLD induced by a high-fat diet combined with 30% fructose in drinking water.
resultsTreatment with EDL6D exerted both preventive and therapeutic effects, significantly reducing hepatic fat accumulation and promoting regression of MASLD compared with vehicle-treated mice. Mechanistically, EDL6D downregulated the mRNA expression and protein levels of key lipogenic enzymes, including ATP-citrate lyase, acetyl-CoA carboxylase, and fatty acid synthase, as well as peroxisome proliferator-activated receptor gamma, a central lipogenic transcription factor. Notably, EDL6D prevented the development of mild fibrosis by reducing the expression of collagen type I alpha 1 chain (Col1a1) and transforming growth factor beta 1 (TGF-β1).
conclusionsMASLD remains as an unmet medical need and disease progression to fibrosis represents a major clinical challenge. This study identifies EDL6D as a novel preclinical lead compound that targets both hepatic lipid accumulation and suggests an antifibrotic effect. These findings support the translational potential of bioactive peptides phenocopying SHBG for the treatment and prevention of MASLD.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.